Bayer's Momentum Tested by Earnings and Landmark Legal Verdict
Bayer's recent rally has left investors wondering if it's sustainable.
The stock gained 15.34% in the last 30 trading sessions, but a closer look at its technicals reveals signs of exhaustion.
The Relative Strength Index is 49.6, neither overbought nor oversold, and the gap to its 52-week high remains significant at 14.6%.
A packed macro calendar precedes Bayer's corporate milestones, including a Federal Reserve interest-rate decision on Wednesday, GDP releases from major economies on Thursday, and eurozone inflation data on Friday.
The real directional cues for Bayer won't arrive until August, when the company reports second-quarter earnings on August 4.
Investors will be scrutinizing the split between core earnings and reported results, as special items have weighed heavily on the latter for years.
The far more consequential date falls two weeks later: a Missouri court is scheduled to rule on the largest glyphosate settlement in Bayer's history on August 19.